From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis

Publisher： Bentham Science Publishers

E-ISSN： 1875-6190|15|6|874-891

ISSN： 1570-159X

Source： Current Neuropharmacology, Vol.15, Iss.6, 2017-07, pp. : 874-891

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Teriflunomide: a novel oral treatment for relapsing multiple sclerosis

By Sartori Arianna   Carle Dawn   Freedman Mark S  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 7, 2014-05 ,pp. : 1019-1027

Informa Healthcare

Access to resources Recommend Favorite

Teriflunomide for oral therapy in multiple sclerosis

By Papadopoulou Athina   Kappos Ludwig   Sprenger Till  

Expert Review of Clinical Pharmacology, Vol. 5, Iss. 6, 2012-11 ,pp. : 617-628

Informa Healthcare

Access to resources Recommend Favorite

Oral drugs for the treatment of Multiple Sclerosis

By  

PHARMAKON, Vol. 2, Iss. 6, 2014-11 ,pp. : 396-402

Govi-Verlag

Access to resources Recommend Favorite

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis

By Wiese Michael D  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1025-1035

Informa Healthcare

Access to resources Recommend Favorite

Drugs Treatment of Pain in Multiple Sclerosis

By  

Current Clinical Pharmacology, Vol. 2, Iss. 3, 2007-09 ,pp. : 227-233

Bentham Science Publishers

Access to resources Recommend Favorite